Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462118 | 0.93 | HRH2 (0.63) | HRH2HRH1GAASMYD3KDM5A | |
| SCHEMBL31086828 | 0.84 | HRH2 (0.53) | HRH2HRH1GAASMYD3KDM5A | |
| SCHEMBL3460994 | 0.80 | ACKR3 (0.57) | HRH2HRH1GAASMN1; SMN2GRM5 | |
| SCHEMBL28266316 | 0.79 | SMYD3 (0.66) | GAASMYD3MAPTNPC1RAB9A | |
| SCHEMBL21722409 | 0.79 | HRH2 (0.58) | HRH2HRH1GAASMYD3KDM5A | |
| SCHEMBL3462409 | 0.79 | HRH2 (0.58) | HRH2HRH1GAASMYD3KDM5A | |
| SCHEMBL20451349 | 0.78 | GAA (0.64) | GAASMYD3MAPTNPC1RAB9A | |
| SCHEMBL12218526 | 0.78 | GAA (0.64) | GAASMYD3MAPTNPC1RAB9A | |
| SCHEMBL25135867 | 0.77 | CD38 (0.50) | GAA | |
| SCHEMBL25135852 | 0.77 | CD38 (0.50) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | HRH2 1297/4885HRH1 1436/4885GAA 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.